EUVIMEDEUVIMED entdecken
Klinische StudieOpen Access · CC BY 4.0

Crofelemer for the Management of Neratinib-Associated Diarrhea in Patients With HER2+ Early-Stage Breast Cancer

Saya Jacob, MacKenzie Johnson, Brianna Roque, Laura Quintal, Hope S Rugo, Michelle Melisko, Amy Jo Chien

Clinical Breast Cancer · 2023

DOI: 10.1016/j.clbc.2023.06.014 ↗

Kurz gefasst

Klinische Studie in der Zeitschrift Clinical Breast Cancer, 2023. Verfasst von Saya Jacob und 6 weiteren Autor:innen. Beteiligte Einrichtung: Helen Diller Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA. Hauptthemen laut MEDLINE: Breast Neoplasms, Quinolines. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Puma Biotechnology Inc.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsQuinolinesFemaleHumansAntineoplastic Combined Chemotherapy ProtocolsDiarrheaLoperamideErb-b2 Receptor Tyrosine KinasesProanthocyanidins

Stichwörter der Autor:innen

HER2+ breast cancerLocalized breast cancerSupportive careToxicity managementTyrosine Kinase Inhibitor

Substanzen

LoperamideQuinolinesErb-b2 Receptor Tyrosine KinasescrofelemerProanthocyanidinsneratinib

Autor:innen und Institutionen

  • Helen Diller Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA.
  • Helen Diller Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA. Electronic address: Jo.chien@ucsf.edu.

Förderung

  • Puma Biotechnology Inc

Zitieren

APA

Jacob, S., Johnson, M., Roque, B., Quintal, L., Rugo, H. S., Melisko, M., & Chien, A. J. (2023). Crofelemer for the Management of Neratinib-Associated Diarrhea in Patients With HER2+ Early-Stage Breast Cancer. Clinical Breast Cancer. https://doi.org/10.1016/j.clbc.2023.06.014

Vancouver

Jacob S, Johnson M, Roque B, Quintal L, Rugo HS, Melisko M, et al. Crofelemer for the Management of Neratinib-Associated Diarrhea in Patients With HER2+ Early-Stage Breast Cancer. Clinical Breast Cancer. 2023. doi:10.1016/j.clbc.2023.06.014

BibTeX
@article{Jacob2023,
  author = {Jacob, Saya and Johnson, MacKenzie and Roque, Brianna and Quintal, Laura and Rugo, Hope S and Melisko, Michelle and Chien, Amy Jo},
  title = {Crofelemer for the Management of Neratinib-Associated Diarrhea in Patients With HER2+ Early-Stage Breast Cancer},
  journal = {Clinical Breast Cancer},
  year = {2023},
  doi = {10.1016/j.clbc.2023.06.014}
}
Kostenlos starten →